Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and Evaluation
Niosomes are a stable vesicular system composed of non-ionic surfactants and cholesterol, offering advantages such as enhanced stability and controlled drug release. In this study, a niosomal nanogel loaded with Ebastine was developed to improve patient compliance in treating skin allergic reactions...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Biology and Life Sciences Forum |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-9976/38/1/9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850089962622418944 |
|---|---|
| author | Bhushan R. Rane Aditi P. Padave Ashish S. Jain |
| author_facet | Bhushan R. Rane Aditi P. Padave Ashish S. Jain |
| author_sort | Bhushan R. Rane |
| collection | DOAJ |
| description | Niosomes are a stable vesicular system composed of non-ionic surfactants and cholesterol, offering advantages such as enhanced stability and controlled drug release. In this study, a niosomal nanogel loaded with Ebastine was developed to improve patient compliance in treating skin allergic reactions. Thin-film hydration was employed to prepare niosomes using cholesterol, Span 60, Tween 80, and Ebastine, optimized via Box–Behnken experimental design. A dispersion method incorporating Carbopol 934 was utilized to create a niosomal gel, ensuring effective therapeutic outcomes. The formulation exhibited high drug entrapment efficiency (84.19%), a zeta potential of −27 mV, and vesicle sizes ranging from 100 to 300 nm. Evaluation included FTIR for drug–excipient compatibility, pH assessment, in vitro drug release studies, and stability testing, all yielding acceptable results. The encapsulation of Ebastine within niosomes is driven by critical physicochemical interactions between the drug, cholesterol, and surfactants. These interactions influence the stability, encapsulation efficiency, and release profile of the drug from the niosomal bilayer. Microbial studies indicated significant antimicrobial activity against <i>S. aureus</i>, underscoring its potential as an effective transdermal treatment for skin allergies. |
| format | Article |
| id | doaj-art-c41daf295ea840138ec7697c93e65ed3 |
| institution | DOAJ |
| issn | 2673-9976 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology and Life Sciences Forum |
| spelling | doaj-art-c41daf295ea840138ec7697c93e65ed32025-08-20T02:42:39ZengMDPI AGBiology and Life Sciences Forum2673-99762025-03-01381910.3390/blsf2024038009Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and EvaluationBhushan R. Rane0Aditi P. Padave1Ashish S. Jain2Department of Pharmaceutics, Shri D.D. Vispute, College of Pharmacy & Research Center, New Panvel 410206, IndiaDepartment of Pharmaceutics, Shri D.D. Vispute, College of Pharmacy & Research Center, New Panvel 410206, IndiaDepartment of Pharmaceutics, Shri D.D. Vispute, College of Pharmacy & Research Center, New Panvel 410206, IndiaNiosomes are a stable vesicular system composed of non-ionic surfactants and cholesterol, offering advantages such as enhanced stability and controlled drug release. In this study, a niosomal nanogel loaded with Ebastine was developed to improve patient compliance in treating skin allergic reactions. Thin-film hydration was employed to prepare niosomes using cholesterol, Span 60, Tween 80, and Ebastine, optimized via Box–Behnken experimental design. A dispersion method incorporating Carbopol 934 was utilized to create a niosomal gel, ensuring effective therapeutic outcomes. The formulation exhibited high drug entrapment efficiency (84.19%), a zeta potential of −27 mV, and vesicle sizes ranging from 100 to 300 nm. Evaluation included FTIR for drug–excipient compatibility, pH assessment, in vitro drug release studies, and stability testing, all yielding acceptable results. The encapsulation of Ebastine within niosomes is driven by critical physicochemical interactions between the drug, cholesterol, and surfactants. These interactions influence the stability, encapsulation efficiency, and release profile of the drug from the niosomal bilayer. Microbial studies indicated significant antimicrobial activity against <i>S. aureus</i>, underscoring its potential as an effective transdermal treatment for skin allergies.https://www.mdpi.com/2673-9976/38/1/9niosomesBox–BehnkenEbastineCarbopol 934<i>S. aureus</i> |
| spellingShingle | Bhushan R. Rane Aditi P. Padave Ashish S. Jain Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and Evaluation Biology and Life Sciences Forum niosomes Box–Behnken Ebastine Carbopol 934 <i>S. aureus</i> |
| title | Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and Evaluation |
| title_full | Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and Evaluation |
| title_fullStr | Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and Evaluation |
| title_full_unstemmed | Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and Evaluation |
| title_short | Nano-Encapsulated Ebastine Niosomal Transdermal Nanogel: QBD Model for Allergy Treatment and Evaluation |
| title_sort | nano encapsulated ebastine niosomal transdermal nanogel qbd model for allergy treatment and evaluation |
| topic | niosomes Box–Behnken Ebastine Carbopol 934 <i>S. aureus</i> |
| url | https://www.mdpi.com/2673-9976/38/1/9 |
| work_keys_str_mv | AT bhushanrrane nanoencapsulatedebastineniosomaltransdermalnanogelqbdmodelforallergytreatmentandevaluation AT aditippadave nanoencapsulatedebastineniosomaltransdermalnanogelqbdmodelforallergytreatmentandevaluation AT ashishsjain nanoencapsulatedebastineniosomaltransdermalnanogelqbdmodelforallergytreatmentandevaluation |